tiprankstipranks
TScan Therapeutics (TCRX)
NASDAQ:TCRX
US Market
TCRX
TScan Therapeutics
RESEARCH TOOLSreports

TScan Therapeutics (TCRX) Income Statement

355 Followers

TScan Therapeutics Income Statement

Last quarter (Q4 2025), TScan Therapeutics's total revenue was $2.57M, an increase of 286.02% from the same quarter last year. In Q4, TScan Therapeutics's net income was $-22.98M. See TScan Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 10.32M$ 2.82M$ 21.05M$ 13.54M$ 10.14M
Gross Profit
$ 7.46M$ 2.82M$ 21.05M$ 13.54M$ 10.14M
Operating Expenses
$ 143.27M$ 137.64M$ 114.51M$ 80.17M$ 58.78M
Depreciation and Amortization
$ 2.87M$ 4.11M$ 5.36M$ 5.14M$ 3.33M
EBITDA
$ -132.95M$ -119.74M$ -80.10M$ -59.91M$ -45.30M
Operating Income
$ -135.81M$ -134.82M$ -93.46M$ -66.64M$ -48.64M
Other Income/Expenses
$ 6.05M$ 7.32M$ 4.24M$ 415.00K$ 16.00K
Pretax Income
$ -129.77M$ -127.50M$ -89.22M$ -66.22M$ -48.63M
Net Income
$ -129.77M$ -127.50M$ -89.22M$ -66.22M$ -48.63M
Per Share Metrics
Basic EPS
$ -1.00$ -1.14$ -1.36$ -2.74$ -2.03
Diluted EPS
$ -1.00$ -1.14$ -1.36$ -2.74$ -2.03
Weighted Average Shares Outstanding
 129.86M 111.99M 65.60M 24.05M 23.91M
Weighted Average Shares Outstanding (Diluted)
 129.86M 111.99M 65.60M 24.05M 23.91M
Currency in USD

TScan Therapeutics Earnings and Revenue History